PRNB News and Press, Principia Biopharma Inc. From 04/04/19

Principia Biopharma ( PRNB ) is a small-cap biopharma with its lead candidate in phase 3 targeting pemphigus vulgaris or PV, an autoimmune disease causing dermal or mucosal blisters. There are existing medications, but treatment may take years, so people often use a lower dose of medication no...

Gainers: MKTX   +3.8% . WTRE   +3.1% . CBLK   +3.1% . PRNB   +2.1% . VALE   +1.7% . More news on: MarketAxess Holdings Inc., Watford Holdings Ltd., Carbon Black, Inc., Stocks on the move, Read more ...

The FDA approves Merck KGaA ( OTCPK:MKGAY ) unit EMD Serono's Mavenclad (cladribine) tablets for the treatment of relapsing forms of multiple sclerosis (MS). More news on: Merck KGaA ADR, Celgene Corporation, Roche Holding AG, Healthcare stocks news, Read more ...

The FDA approves Novartis' (NYSE: NVS ) Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome (defined as a first episode of neurologic symptoms that lasts at least 24 hours and is caused by inflammation or demyelinatio...

Principia Biopharma (NASDAQ: PRNB ): Q4 GAAP EPS of $0.37 beats by $0.96 . More news on: Principia Biopharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

SOUTH SAN FRANCISCO, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced fi...

-- Principia and AbbVie mutually agree to end collaboration -- -- Preclinical stage program focused on development of oral immunoproteasome inhibitors to treat inflammation and autoimmune disorders -- SOUTH SAN FRANCISCO, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma ...

No IPOs are scheduled for the week ahead, unusual for mid-March. It may be due to some lingering effects from the government shutdown, as the SEC works through its backlog. With the VIX Volatility Index comfortably below 20 and strong YTD returns in the IPO Index, the IPO market is receptive...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...

Thinly traded Principia Biopharma ( PRNB +1.1% ) is up, albeit on turnover of only 5K shares, following its announcement of positive results from an open-label Phase 2 clinical trial evaluating its lead candidate, Orphan Drug-tagged PRN1008, in pemphigus patients. The data were present...